Last reviewed · How we verify
FCFD4514S
At a glance
| Generic name | FCFD4514S |
|---|---|
| Sponsor | Genentech, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy (PHASE1)
- An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy (PHASE2)
- A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FCFD4514S CI brief — competitive landscape report
- FCFD4514S updates RSS · CI watch RSS
- Genentech, Inc. portfolio CI